Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
Shuichi MizutaTomotaka UgaiHarumi KatoNoriko DokiShuichi OtaToshiro KawakitaYuta KatayamaMineo KurokawaHirohisa NakamaeShingo YanoYuichiro NawaYoshinobu KandaTakahiro FukudaYoshiko AtsutaShinichi KakoPublished in: International journal of hematology (2022)
We compared the outcomes of autologous stem cell transplantation (auto-SCT) with those of allogeneic stem cell transplantation (allo-SCT) from a human leukocyte antigen-matched related donor in patients with Philadelphia chromosome-negative B-lineage acute lymphoblastic leukemia (ALL). Newly diagnosed patients who underwent allo-SCT (n = 486) or auto-SCT (n = 99) after achieving first complete remission (CR) were included. Propensity score matching (PS) and an inverse probability of the treatment weighting (IPTW) analysis were applied to compensate for imbalances in baseline characteristics. The 5 years rates of overall survival (OS) among those in the PS-matched cohorts were 57% [95% confidence interval (CI) 46-67%] for those who received allo-SCT and 44% (95% CI 33-54%) for those who received auto-SCT. Multivariable, propensity score-matched, and IPTW analyses all revealed no statistically significant differences in OS between the two groups [hazard ratios (HR) 0.81, 95% CI 0.53-1.27, p = 0.36; HR 0.84, 95% CI 0.40-1.78, p = 0.65; HR 0.71, 95% CI 0.25-2.02, p = 0.53, respectively]. Prospective trials that include autologous transplantation as a treatment option are needed to examine the potential of autologous transplantation.
Keyphrases
- stem cell transplantation
- acute lymphoblastic leukemia
- high dose
- newly diagnosed
- cell therapy
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- platelet rich plasma
- end stage renal disease
- single cell
- endothelial cells
- ejection fraction
- chronic kidney disease
- stem cells
- low dose
- risk assessment
- rheumatoid arthritis
- adipose tissue
- human health
- systemic lupus erythematosus
- skeletal muscle
- replacement therapy